Chinese state drug authorities approved Sichuan Hexie Shuangma (SHE:000935) subsidiary Hubei Jianxiang Biopharmaceutical's active pharmaceutical ingredient application for leuprorelin acetate, according to a Friday filing with the Shenzhen bourse.
The drug helps stop the secretion of gonadotropin.
Leuprorelin acetate is currently approved for endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious or unusually early puberty, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments